Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerOlivia Pagani, Prudence A. Francis, Hervé Bonnefoi et al.|New England Journal of Medicine|2014Cited by 751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A. Francis, Meredith M. Regan, Olivia Pagani et al.|New England Journal of Medicine|2018Cited by 684
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT TrialsMeredith M. Regan, Richard D. Gelber, Prudence A. Francis et al.|Journal of Clinical Oncology|2016Cited by 184
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Barbara Walley, Weixiu Luo et al.|The Lancet Oncology|2015Cited by 179
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFTOlivia Pagani, Prudence A. Francis, Gini F. Fleming et al.|Journal of Clinical Oncology|2019Cited by 150